Patent · US Active

MUC1 based glycolipopeptide vaccine with adjuvant

US8329639B2 · kind B2 · utility

0Cited by
32References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 19, 2012
Grant dateDec 11, 2012
Priority date
Expiry dateJul 19, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/585
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.